DDInter119 DDInter1281
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer.
Neratinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Neratinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Neratinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Binimetinib
Neratinib {u} may lead to a major life threatening interaction when taken with {v} Colchicine
Neratinib {u} may lead to a major life threatening interaction when taken with {v} Fedratinib
Neratinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Neratinib may lead to a major life threatening interaction when taken with Colchicine
Neratinib may lead to a major life threatening interaction when taken with Fedratinib